MedTrace Logo

Topical Brimonidine to Reduce Inflammation After IPL-treatment in Patients With Facial Telangiectasias

NCT02761174 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2018-01-05

No results posted yet for this study

Summary

The aim of the study is to investigate whether brimonidine cream can reduce IPL-induced inflammation in terms of redness, swelling and pain in patients with facial vascular lesions (telangiectasias). Furthermore, the effect of brimonidine cream on IPL-efficacy is evaluated one month after final IPL-treatment.

The hypothesis is that brimonidine, which has been proved effective in reduction of symptomatic erythema in patients with rosacea, also may have the ability to reduce IPL-induced erythema. Since the potential reduction in erythema is caused by vasoconstriction, brimonidine may further reduce IPL-induced oedema and pain.

Conditions

  • Telangiectasias

Interventions

DRUG

Brimonidine

Patients receive brimonidine to half of their face, whereas the other half receives no treatment and thereby patients are their own control

OTHER

IPL+air-cooling

IPL+air-cooling are applied to the whole face and the control side thereby only receives IPL+air-cooling

Sponsors & Collaborators

  • Skinperium, Christine Dierickx

    collaborator UNKNOWN

  • Ellipse A/S Agern Allé 11, 2970 Hørsholm

    collaborator UNKNOWN

  • Merete Haedersdal

    lead OTHER

Principal Investigators

  • Merete Hædersdal, Prof., MD · Department of Dermatology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-13
Primary Completion
2016-07-11
Completion
2017-01-13

Countries

  • Denmark

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02761174 on ClinicalTrials.gov